MAPK14 and chronic obstructive pulmonary disease: Accumulating evidence under human clinical trials shows that p38 inhibitors are a promising therapeutic strategy to control inflammatory diseases, for example, RA and chronic obstructive pulmonary disease (COPD) [52].